
Please try another search
Prestige BioPharma Limited, a biopharmaceutical company, engages in the research and development and marketing of biosimilars, first-in-class antibody drugs, and vaccines. The company primarily engages in the development of biosimilars, including Trastuzumab, which is under regulatory review for breast and gastric cancer; Bevacizumab, in phase 3 clinical study for solid tumours; Adalimumab, in phase 1 clinical study for arthritis. It is developing first-in-class antibody therapeutics, such as monoclonal antibodies, bispecific antibodies, and fusion antibodies for life-threatening diseases; vaccines for COVID-19 virus; and diagnostic kits for the detection of pancreatic adenocarcinoma upregulated factor. Prestige BioPharma Limited was incorporated in 2015 and is headquartered in Singapore.
Name | Age | Since | Title |
---|---|---|---|
So-yeon Park | 59 | 2015 | Chairman & CEO |
Seung-Joo Oh | 48 | 2020 | Independent Director |
Jinwoo Kim | 60 | 2016 | CFO & Director |
Kyunghee Jeon | 56 | 2020 | Independent Director |
Kok Fatt Lee | 51 | 2020 | Independent Director |
Eui Kyung Lee | 65 | 2020 | Independent Director |
Kue-Ho Bang | 61 | 2020 | Independent Director |
Kang Lin Ong | 46 | 2023 | Independent Director |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review